The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats

Liver International

Volumn 29, Issue 1, 2009, Pages 25-36

  Yu, Jun ^a   Hui, Alex Y ^a   Chu, Eagle S H ^a   Go, Minnie Y Y ^a   Cheung, Kin F ^a   Wu, Chung W ^a   Chan, Henry L Y ^a   Sung, Joseph J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bile duct ligation; Celecoxib; HSC T6; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; BILIRUBIN; CELECOXIB; COLLAGEN; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BILE DUCT LIGATION; CHOLESTASIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; GENE EXPRESSION; LIVER FIBROSIS; LIVER PROTECTION; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; TOXICITY TESTING;

ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BILE DUCTS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIGATION; LIVER; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PYRAZOLES; RATS; SULFONAMIDES; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57749190824     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01760.x     Document Type: Article

References (35)

1. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105.
2. Brenner DA, Waterboer T, Choi SK, et al. New aspects of hepatic fibrosis. J Hepatol 2000; 32(Suppl.): 32-8.
3. Endoh T, Tang Q, Denda A, et al. Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, l-amino acid defined diet in rats. Carcinogenesis 1996; 17: 467-75.
4. Clària J, Arroyo V. Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver disease. Prostaglandins Other Lipid Mediat 2003; 72: 19-33.
5. Bosch-Marce M, Claria J, Titos E, et al. Selective inhibition of cyclooxygenase-2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999; 116: 1167-75.
6. Lopez-Parra M, Claria J, Planaguma A, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002; 135: 891-900.
7. Cheng AS, Chan HL, Leung WK, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: Implication of HBx in upregulation of COX-2. Mod Pathol 2004; 17: 1169-79.
8. Mohammed NA, El Aleem SA, El Hafiz HA, et al. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: A possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol 2004; 57: 350-4.
9. Nunez O, Fernandez-Martinez A, Majano PL, et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: Role of viral core and NS5A proteins. Gut 2004; 53: 1665-72.
10. FitzGerald G, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42.
11. Guevara M, Abecasis R, Terg R. Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study. Scand J Gastroenterol 2004; 39: 385-6.
12. Bresalier RS, Sandler RS, Quan H, et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
13. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
14. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-73.
15. White WB, Strand V, Roberts R, et al. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004; 11: 244-50.
16. Hui AY, Leung WK, Chan HL, et al. Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 2006; 26: 125-36.
17. Akahoshi T, Tanigawa T, Sarfeh IJ, et al. Selective cyclooxygenase (COX) inhibition causes damage to portal hypertensive gastric mucosa: Roles of nitric oxide and NF-kappaB. FASEB J 2005; 19: 1163-5.
18. Chiou SK, Tanigawa T, Akahoshi T, et al. Survivin: A novel target for indomethacin-induced gastric injury. Gastroenterology 2005; 128: 63-73.
19. Hu PJ, Yu J, Zeng ZR, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004; 53: 195-200.
20. Reddy GK, Envenemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29: 225-9.
21. Zhang MZ, Yao B, Cheng HF, et al. Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors. Proc Natl Acad Sci USA 2006; 103: 16045-50.
22. Vio CP, Balestrini C, Recabarren M, et al. Postnatal development of cyclooxygenase-2 in the rat kidney. Immunopharmacology 1999; 44: 205-10.
23. Wanless IR, Belgiorno J, Huet PM. Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: Morphology and inhibition of fibrogenesis by dipyridamole. Hepatology 1996; 24: 855-64.
24. Yokoyama Y, Xu H, Kresge N, et al. Role of thromboxane A2 in early BDL induced portal hypertension. Am J Physiol Gastrointest Liver Physiol 2003; 284: G453-60.
25. Miyamoto K, Miyake S, Mizuno M, et al. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 2006; 129: 1984-92.
26. Maier TJ, Janssen A, Schmidt R, et al. Targeting the beta-catenin/APC pathway: A novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005; 19: 1353-5.
27. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999; 5: 4005-12.
28. Sung YK, Hwang SY, Kim JO, et al. The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells 2004; 17: 35-8.
29. Yu J, Ip E, Dela Peña A, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology 2006; 43: 826-36.
30. Cheng AS, Chan HL, To KF, et al. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 2004; 24: 853-60.
31. Rahman MA, Dhar DK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: Possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001; 7: 1325-32.
32. Arafa HM, Abdel-Wahab MH, El-Shafeey MF, et al. Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. Eur J Pharmacol 2007; 564: 181-9.
33. Planaguma A, Claria J, Miquel R, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPAR gamma activation. FASEB J 2005; 19: 1120-2.
34. Yamamoto H, Kondo M, Nakamori S, et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 2003; 125: 556-71.
35. Shen W, Li Y, Tang Y, et al. NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis. Am J Pathol 2005; 167: 1105-17.